Buprenorphine for neuropathic pain in adults (Review)


Buprenorphine for neuropathic pain in adults.
DOI: 10.1002/14651858.CD011603.pub2.

www.cochranelibrary.com
# Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Header</td>
<td>1</td>
</tr>
<tr>
<td>Abstract</td>
<td>1</td>
</tr>
<tr>
<td>Plain Language Summary</td>
<td>2</td>
</tr>
<tr>
<td>Background</td>
<td>2</td>
</tr>
<tr>
<td>Objectives</td>
<td>5</td>
</tr>
<tr>
<td>Methods</td>
<td>5</td>
</tr>
<tr>
<td>Figure 1</td>
<td>6</td>
</tr>
<tr>
<td>Results</td>
<td>8</td>
</tr>
<tr>
<td>Discussion</td>
<td>8</td>
</tr>
<tr>
<td>Authors' Conclusions</td>
<td>9</td>
</tr>
<tr>
<td>Acknowledgements</td>
<td>9</td>
</tr>
<tr>
<td>References</td>
<td>10</td>
</tr>
<tr>
<td>Characteristics of Studies</td>
<td>14</td>
</tr>
<tr>
<td>Data and Analyses</td>
<td>16</td>
</tr>
<tr>
<td>What's New</td>
<td>16</td>
</tr>
<tr>
<td>History</td>
<td>16</td>
</tr>
<tr>
<td>Contributions of Authors</td>
<td>16</td>
</tr>
<tr>
<td>Declarations of Interest</td>
<td>16</td>
</tr>
<tr>
<td>Sources of Support</td>
<td>16</td>
</tr>
<tr>
<td>Differences Between Protocol and Review</td>
<td>17</td>
</tr>
<tr>
<td>Notes</td>
<td>17</td>
</tr>
<tr>
<td>Index Terms</td>
<td>17</td>
</tr>
</tbody>
</table>
Buprenorphine for neuropathic pain in adults

Philip J Wiffen¹, Sheena Derry¹, R Andrew Moore¹, Cathy Stannard², Dominic Aldington³, Peter Cole⁴, Roger Knaggs⁵

¹Pain Research and Nuffield Department of Clinical Neurosciences (Nuffield Division of Anaesthetics), University of Oxford, Oxford, UK. ²Pain Clinic, Macmillan Centre, Frenchay Hospital, Bristol, UK. ³Royal Hampshire County Hospital, Winchester, UK. ⁴Oxford Pain Relief Unit, Churchill Hospital, Oxford University Hospitals NHS Trust, Oxford, UK. ⁵School of Pharmacy, University of Nottingham, Nottingham, UK

Contact address: R Andrew Moore, Pain Research and Nuffield Department of Clinical Neurosciences (Nuffield Division of Anaesthetics), University of Oxford, Pain Research Unit, Churchill Hospital, Oxford, Oxfordshire, OX3 7LE, UK. andrew.moore@ndcn.ox.ac.uk.

Editorial group: Cochrane Pain, Palliative and Supportive Care Group.


Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

ABSTRACT

Background

Opioid drugs, including buprenorphine, are commonly used to treat neuropathic pain, and are considered effective by some professionals. Most reviews have examined all opioids together. This review sought evidence specifically for buprenorphine, at any dose, and by any route of administration. Other opioids are considered in separate reviews.

Objectives

To assess the analgesic efficacy of buprenorphine for chronic neuropathic pain in adults, and the adverse events associated with its use in clinical trials.

Search methods

We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, and EMBASE from inception to 11 June 2015, together with reference lists of retrieved papers and reviews, and two online study registries.

Selection criteria

We included randomised, double-blind studies of two weeks' duration or longer, comparing any oral dose or formulation of buprenorphine with placebo or another active treatment in chronic neuropathic pain.

Data collection and analysis

Two review authors independently searched for studies, extracted efficacy and adverse event data, and examined issues of study quality. We did not carry out any pooled analyses.

Main results

Searches identified 10 published studies, and one study with results in ClinicalTrials.gov. None of these 11 studies satisfied our inclusion criteria, and so we included no studies in the review.
PLAIN LANGUAGE SUMMARY

Buprenorphine for neuropathic pain in adults

Neuropathic pain is pain coming from damaged nerves. It is different from pain messages that are carried along healthy nerves from damaged tissue (for example, a fall or cut, or arthritic knee). Neuropathic pain is often treated by different medicines (drugs) to those used for pain from damaged tissue, which we often think of as painkillers. Medicines that are sometimes used to treat depression or epilepsy can be very effective in some people with neuropathic pain. But sometimes opioid painkillers are used to treat neuropathic pain.

Opioid painkillers are drugs like morphine. Morphine is derived from plants, but many opioids are also made by chemical synthesis rather than being extracted from plants. Buprenorphine is one of these synthetic opioids. It is available in numerous countries for use as a painkiller, and can be given by injection, as a tablet placed under the tongue, or as a patch that delivers the drug to the body through the skin.

In June 2015, we performed searches to look for clinical trials where buprenorphine was used to treat neuropathic pain in adults. We found no study that did this, and that met our requirements for the review.

There is no evidence to support or refute the suggestion that buprenorphine works in any neuropathic pain condition. Large, properly conducted new clinical trials would be needed to provide evidence that buprenorphine worked in neuropathic pain conditions.

BACKGROUND

This review is based on a template for reviews of drugs used to relieve neuropathic pain. The aim is for all reviews to use the same methods, based on new criteria for what constitutes reliable evidence in chronic pain (Moore 2010a; Appendix 1).

Description of the condition

The 2011 International Association of the Study of Pain definition of neuropathic pain is “pain caused by a lesion or disease of the somatosensory system” (Jensen 2011), based on an earlier consensus meeting (Treede 2008). Neuropathic pain is a consequence of a pathological maladaptive response of the nervous system to ‘damage’ from a wide variety of potential causes. It is characterised by pain in the absence of a noxious stimulus and may be spontaneous (continuous or paroxysmal) in its temporal characteristics or be evoked by sensory stimuli (dynamic mechanical allodynia where pain is evoked by light touch of the skin). Neuropathic pain is associated with a variety of sensory loss (numbness) and sensory gain (allodynia) clinical phenomena, the exact pattern of which vary between patient and disease, perhaps reflecting different pain mechanisms operating in an individual patient and therefore potentially predictive of response to treatment (Demant 2014; Helfert 2015; von Hehn 2012). Pre-clinical research hypothesises a bewildering array of possible pain mechanisms that may operate in people with neuropathic pain, which largely reflect pathophysiological responses in both the central and peripheral nervous systems, including neuronal interactions with immune cells (Baron 2012; Calvo 2012; von Hehn 2012). Overall, the treatment gains in neuropathic pain, to even the most effective of available drugs, are modest (Finnerup 2015; Moore 2013a), and a robust classification of neuropathic pain is not yet available (Finnerup 2013). Neuropathic pain is usually divided according to the cause of nerve injury. There may be many causes, but some common causes of neuropathic pain include diabetes (painful diabetic neuropathy (PDN)), shingles (postherpetic neuralgia (PHN)), amputation (phantom limb pain), neuropathic pain after surgery or trauma, stroke or spinal cord injury, trigeminal neuralgia, and human immunodeficiency virus (HIV) infection. Many people with neuropathic pain conditions are significantly disabled with moderate or severe pain for many years. Chronic pain
conditions comprised five of the 11 top-ranking conditions for years lived with disability in 2010 (Vos 2012), and are responsible for considerable loss of quality of life, employment, and increased healthcare costs (Moore 2014a).

In systematic reviews, the overall prevalence of neuropathic pain in the general population is reported to be between 7% and 10% (van Hecke 2014), and about 7% in a systematic review of studies published since 2000 (Moore 2014a). In individual countries, prevalence rates have been reported as 3.3% in Austria (Gustorff 2008), 6.9% in France (Bouhassira 2008), and up to 8% in the UK (Torrance 2006). Some forms of neuropathic pain, such as PDPN and post-surgical chronic pain (which is often neuropathic in origin), are increasing (Hall 2008). The prevalence of PHN is likely to fall if vaccination against the herpes virus becomes widespread. Estimates of incidence vary between individual studies for particular origins of neuropathic pain, often because of small numbers of cases. In primary care in the UK between 2002 and 2005, the incidences (per 100,000 person-years’ observation) were 28 (95% confidence interval (CI) 27 to 30) for PHN, 27 (26 to 29) for trigeminal neuralgia, 0.8 (0.6 to 1.1) for phantom limb pain, and 21 (20 to 22) for PDPN (Hall 2008). However, the incidence of trigeminal neuralgia has also been estimated at 4 in 100,000 per year (Katsik 1991; Rappaport 1994), and 12.6 per 100,000 person-years for trigeminal neuralgia and 3.9 per 100,000 person-years for PHN in a study of facial pain in the Netherlands (Koopman 2009). One systematic review of chronic pain demonstrated that some neuropathic pain conditions, such as PDPN, can be more common than other neuropathic pain conditions, with prevalence rates up to 400 per 100,000 person-years (McQuay 2007).

Neuropathic pain is known to be difficult to treat effectively, with only a minority of individuals experiencing a clinically relevant benefit from any one intervention. A multidisciplinary approach is now advocated, with pharmacological interventions being combined with physical or cognitive interventions, or both. Conventional analgesics are usually not effective, but without evidence to support or refute that view. Some people with neuropathic pain may derive some benefit from a topical lidocaine patch or low concentration topical capsaicin, though evidence about benefits is uncertain (Derry 2012; Derry 2014). High concentration topical capsaicin may benefit some people with PHN (Derry 2013). Treatment for neuropathic pain is more usually by so-called unconventional analgesics (pain modulators) such as antidepressants like duloxetine and amitriptyline (Lunn 2014; Moore 2012b; Sultan 2008), or antiepileptics like gabapentin or pregabalin (Moore 2009; Moore 2014b; Wiffen 2013). The proportion of people who achieve worthwhile pain relief (typically at least 50% pain intensity reduction; Moore 2013b) is small, generally only 10% to 25% more than with placebo, with numbers needed to treat for an additional beneficial outcome (NNT) usually between 4 and 10 (Kalso 2013; Moore 2013a). Neuropathic pain is not particularly different from other chronic pain conditions in that only a small proportion of trial participants have a good response to treatment (Moore 2013a).

The current National Institute for Health and Care Excellence (NICE) guidance suggests offering a choice of amitriptyline, duloxetine, gabapentin, or pregabalin as initial treatment for neuropathic pain (with the exception of trigeminal neuralgia), with switching if first, second, or third drugs tried are not effective or not tolerated (NICE 2013). This concurs with other recent guidance (Finnerup 2015).

Description of the intervention

Buprenorphine is a thebaine derivative opioid drug, classified as a step III opioid analgesic by the World Health Organization (WHO 1996). It has mixed agonistic and antagonistic properties, with opioid agonistic activity exerted on mu-opioid receptors and the ORL-1 receptor; it is a kappa- and delta-opioid receptor antagonist (Kress 2009; Pergolizzi 2010; Walsh 2003). Buprenorphine is metabolised predominantly by the liver and excreted in bile after de-alkylation and glucuronidation, though hepatic extraction from blood may be more complicated (Bullingham 1984). The pharmacokinetics of buprenorphine vary with route of administration. While the sublingual and intramuscular routes produce similar outcomes in terms of pain relief, when taken orally, buprenorphine undergoes extensive pre-systemic elimination (Bullingham 1981; Bullingham 1983).

Buprenorphine is available in numerous countries for use as an analgesic, and can be given by injection, as a sublingual tablet, or as a transdermal patch (or plaster). Typical analgesic doses of buprenorphine are 0.3 to 0.6 mg (intramuscular or intravenous) and its analgesic effects last about six hours. Sublingual buprenorphine doses are typically 200 to 400 micrograms (µg) every six to eight hours. It is prescribed in the management of cancer pain, but not typically as a first-line opioid. It is also used in opioid-dependence (Foster 2013).

Oral bioavailability of buprenorphine is low (15%) due to extensive first-pass metabolism in the gastrointestinal mucosa and liver. It is rapidly absorbed via the oral mucosa after sublingual administration, but absorption into the systemic circulation is slow (maximum is 30 minutes to 3.5 hours after a single dose; one to two hours with repeat dosing; Elkader 2005). However, it does have a long duration of action (six to eight hours), which is thought to be due to an unusually slow dissociation constant for the drug-receptor complex. Naloxone is relatively ineffective in reversing opioid effects from buprenorphine, despite naloxone having high affinity for the mu-receptor (Gal 1989).

There was a ceiling effect for respiratory depression within the doses studied, but not for analgesia (Dahan 2005; Dahan 2006). While buprenorphine has been shown to slow intestinal transit, it possibly does this less than morphine (Bach 1991); importantly, constipation as an adverse effect may be less severe (Pace 2007). Buprenorphine also exerts little or no pressure on pancreatic...
atic and biliary ducts, distinguishing it from morphine in this respect (Staritz 1986). Compared with other opioids, buprenorphine causes little or no immunosuppression (Budd 2004; Sacerdote 2000; Sacerdote 2008). Buprenorphine does not accumulate in renal failure and it is not removed by haemodialysis, and analgesia is unaffected (Filitz 2006; Hand 1990).

Because buprenorphine is highly lipid-soluble, it is ideal for transdermal delivery. Buprenorphine patch preparations for twice weekly or weekly use are available with a range of transdermal drug delivery rates (5, 10, 20, 35, 52.5, 70 µg/hour). NICE suggests that a transdermal buprenorphine patch of 20 µg/hour equates to approximately 30 mg of oral morphine daily (NICE 2012). Buprenorphine via either the transdermal or injectable route is approved for managing moderate to severe chronic pain. Sublingual tablets and a sublingual film preparations are also available in some countries and are sometimes combined with naloxone. While these are usually used for the treatment of opioid addiction, some sublingual tablets (200 and 400 µg) without naloxone are available for chronic moderate to severe pain. Transdermal buprenorphine has been suggested to be of value in treating chronic non-cancer pain (Kusnik 2008; Sirtl 2005), including neuropathic pain after traumatic amputation, central neuropathic pain, and HIV neuropathy (Canneti 2013; Hakl 2012; Licina 2013; Weiner 2012). However, these are case reports, case series, or post-marketing analyses rather than randomised trials.

How the intervention might work
Opioids such as buprenorphine bind to specific opioid receptors in the nervous system and other tissues; there are three principal classes of receptors (mu, kappa, and delta) although others have been suggested, and subtypes of receptors are considered to exist. Binding of opioid agonists such as buprenorphine to receptors brings about complex cellular changes, outcomes of which include decreased perception of pain, decreased reaction to pain, and increased pain tolerance. Opioids from plant sources have been used for thousands of years to treat pain.

Why it is important to do this review
One UK survey found that weak and strong opioids were used frequently for treating neuropathic pain (Hall 2013). Many clinicians (primary care and pain specialists) consider that buprenorphine has an important place in the management of chronic pain conditions (Pergolizzi 2010). When compared with other opioids, buprenorphine has a better adverse effect and safety profile. Despite this, buprenorphine (patches in particular) is often ‘blacklisted’ on formularies, meaning that prescribing the drug is not approved or allowed. This is reported to be on the basis of lack of good-quality evidence. Since the early-2000s, a marked increase in prescribing of opioids for non-cancer pain in general despite a relatively modest evidence base has, in some countries, led to widespread diversion with consequent abuse, misuse, and mortality (Franklin 2014). Concurrently, suspicion has arisen that opioid-induced hyperalgesia, together with tolerance to the analgesic effects of opioids, may in reality result in a lesser degree of benefit for opioids in neuropathic pain than previously assumed.

The standards used to assess evidence in chronic pain trials have evolved substantially in recent years, with particular attention being paid to trial duration, withdrawals, and statistical imputation following withdrawal, all of which can substantially alter estimates of efficacy. The most important change is the move from using mean pain scores, or mean change in pain scores, to the number of people who have a large decrease in pain (by at least 50%) and who continue in treatment, ideally in trials of eight to 12 weeks’ duration or longer. Pain intensity reduction of 50% or more correlates with improvements in co-morbid symptoms, function, and quality of life. These standards are set out in the PaPaS Author and Referee Guidance for pain studies of the Cochrane Pain, Palliative and Supportive Care Group (PaPaS 2012). This Cochrane review assessed evidence using methods that make both statistical and clinical sense, and used developing criteria for what constitutes reliable evidence in chronic pain (Moore 2010a). For inclusion and analysis, trials had to meet a minimum of reporting quality (blinding, randomisation), validity (duration, dose and timing, diagnosis, outcomes, etc), and size (ideally at least 500 participants in a comparison in which the NNT is 4 or above; Moore 1998). This approach sets high standards for the demonstration of efficacy and marks a departure from how reviews were conducted previously.

Taking this newer, more rigorous approach is particularly important for opioids in chronic non-cancer pain. Opioids in clinical trials in non-cancer pain are associated with very high withdrawal rates of up to 60% over about 12 weeks (Moore 2010b). Many withdrawals occur within the first few weeks, when people experience pain relief but cannot tolerate the drug. The common practice of using the last observed results carried forward to the end of the trial many weeks later (last observation carried forward (LOCF)) can, therefore, produce results based largely on people who are no longer in the trial, and who in the real world could not achieve pain relief because they could not take the tablets. The newer standards, outlined in Appendix 1, would not allow this and can produce very different results. For example, one large analysis of pooled data from trials in osteoarthritis and chronic low back pain conducted over about 12 weeks judged oxycodone effective, but an analysis of the same data using the new clinically meaningful standards showed it to be significantly worse than placebo (Lange 2010).

One previous Cochrane review demonstrated the limitations of our knowledge about opioids in neuropathic pain, except in short duration studies of 24 hours or less (McNicol 2013). These limitations were confirmed by a review specific to oxycodone (Gaskell 2014). A review specific to buprenorphine is timely.
OBJECTIVES

To assess the analgesic efficacy of buprenorphine for chronic neuropathic pain in adults, and the adverse events associated with its use in clinical trials.

METHODS

Criteria for considering studies for this review

Types of studies

We included randomised controlled trials (RCTs) with double-blind assessment of participant outcomes following two weeks of treatment or longer, though the emphasis of the review was on studies of eight weeks or longer. We required full journal publication, with the exception of online clinical trial results summaries of otherwise unpublished clinical trials and abstracts with sufficient data for analysis. We did not include short abstracts (usually meeting reports). We excluded studies that were non-randomised, studies of experimental pain, case reports, and clinical observations.

Types of participants

Studies included adults aged 18 years and above with one or more chronic neuropathic pain condition including (but not limited to):

1. cancer-related neuropathy;
2. central neuropathic pain;
3. complex regional pain syndrome (CRPS) Type II;
4. human immunodeficiency virus (HIV) neuropathy;
5. painful diabetic neuropathy (PDN);
6. phantom limb pain;
7. postherpetic neuralgia (PHN);
8. postoperative or traumatic neuropathic pain;
9. spinal cord injury;
10. trigeminal neuralgia.

Where studies included participants with more than one type of neuropathic pain, we planned to analyse results according to the primary condition.

Types of interventions

Buprenorphine at any dose, by any route, administered for the relief of neuropathic pain and compared with placebo or any active comparator.

Types of outcome measures

We anticipated that studies would use a variety of outcome measures, with the majority of studies using standard subjective scales (numerical rating scale (NRS) or visual analogue scale (VAS)) for pain intensity or pain relief, or both. We were particularly interested in Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) definitions for moderate and substantial benefit in chronic pain studies (Dworkin 2008). These are defined as:

1. at least 30% pain relief over baseline (moderate);
2. at least 50% pain relief over baseline (substantial);
3. much or very much improved on Patient Global Impression of Change scale (PGIC; moderate);
4. very much improved on PGIC (substantial).

These outcomes are different from those used in many earlier reviews, concentrating as they do on dichotomous outcomes where pain responses do not follow a normal (Gaussian) distribution. People with chronic pain desire high levels of pain relief, ideally more than 50% pain intensity reduction, and ideally having no worse than mild pain (Moore 2013b; O’Brien 2010). We planned to include a ‘Summary of findings’ table as set out in the author guide (PaPaS 2012). We have not included a ‘Summary of findings’ table because there was no useful information to include.

Primary outcomes

1. Participant-reported pain relief of 30% or greater.
2. Participant-reported pain relief of 50% or greater.
3. PGIC much or very much improved.
4. PGIC very much improved.

Secondary outcomes

1. Any pain-related outcome indicating some improvement.
2. Withdrawals due to lack of efficacy, adverse events, and for any cause.
3. Participants experiencing any adverse event.
4. Participants experiencing any serious adverse event. Serious adverse events typically include any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, is an ‘important medical event’ that may jeopardise the person, or may require an intervention to prevent one of the above characteristics or consequences.
5. Specific adverse events, particularly somnolence and dizziness.

Search methods for identification of studies
Electronic searches
We search the following databases, without language restrictions.
1. Cochrane Central Register of Controlled Trials (CENTRAL, via the Cochrane Register of Studies Online database (CRSO)) to 11 June 2015.
2. MEDLINE (via Ovid) from 1946 to 11 June 2015.
3. EMBASE (via Ovid) from 1974 to 11 June 2015.
The search strategies for CENTRAL, MEDLINE, and EMBASE are listed in Appendix 2, Appendix 3, and Appendix 4, respectively.

Searching other resources
We reviewed the bibliographies of any RCTs identified and re-view articles, and searched clinical trial databases (ClinicalTrials.gov (ClinicalTrials.gov) and World Health Organization International Clinical Trials Registry Platform (ICTRP) (apps.who.int/trialsearch)) to identify additional published or unpublished data. We did not contact investigators or study sponsors.

Data collection and analysis
We planned to perform separate analyses according to particular neuropathic pain conditions. We planned to combine different neuropathic pain conditions in analyses for exploratory purposes only.

Selection of studies
We determined eligibility by reading the abstract of each study identified by the search. We eliminated studies that clearly did not satisfy the inclusion criteria, and obtained full copies of the remaining studies. Two review authors made the decisions. Two review authors read these studies independently and reached agreement by discussion. We did not anonymise the studies in any way before assessment. We have included a Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow chart (Liberati 2009; Figure 1).

Figure 1. Study flow diagram.

Data extraction and management
We planned that two review authors would extract data independently using a standard form and check for agreement before entry into Review Manager 5 (RevMan 2014), or any other analysis tool. We planned to include information about the pain condition and number of participants treated, drug and dosing regimen, study design (placebo or active control), study duration and follow-up, analgesic outcome measures and results, withdrawals, and adverse events (participants experiencing any adverse event or serious adverse event).
and adapted from those used by the Cochrane Pregnancy and Childbirth Group, with any disagreements resolved by discussion. We planned to assess the following for each study.

1. Random sequence generation (checking for possible selection bias). We planned to assess the method used to generate the allocation sequence as: low risk of bias (any truly random process, random number table, computer random number generator); unclear risk of bias (when the method used to generate the sequence is not clearly stated). We intended to exclude studies at a high risk of bias that used a non-random process (odd or even date of birth, hospital or clinic record number).

2. Allocation concealment (checking for possible selection bias). The method used to conceal allocation to interventions prior to assignment determines whether intervention allocation could have been foreseen in advance of, or during, recruitment, or changed after assignment. We planned to assess the methods as: low risk of bias (telephone or central randomisation, consecutively numbered, sealed, opaque envelopes); unclear risk of bias (when method not clearly stated). We intended to exclude studies that did not conceal allocation and were, therefore, at a high risk of bias (open list).

3. Blinding of outcome assessment (checking for possible detection bias). We planned to assess the methods used to blind study participants and outcome assessors from knowledge of which intervention a participant received. We planned to assess the methods as: low risk of bias (study stated that it was blinded and described the method used to achieve blinding, identical tablets, matched in appearance and smell); unclear risk of bias (study stated that it was blinded but did not provide an adequate description of how it was achieved). We intended to exclude studies at a high risk of bias that were not double-blind.

4. Incomplete outcome data (checking for possible attrition bias due to the amount, nature, and handling of incomplete outcome data). We planned to assess the methods used to deal with incomplete data as: low risk of bias (less than 10% of participants did not complete the study or used ‘baseline observation carried forward’ analysis, or both); unclear risk of bias (used LOCF analysis); or high risk of bias (used ‘completer’ analysis).

5. Size of study (checking for possible biases confounded by small size). We planned to assess studies as being at low risk of bias (200 participants or more per treatment arm); unclear risk of bias (50 to 199 participants per treatment arm); or high risk of bias (fewer than 50 participants per treatment arm).

**Measures of treatment effect**

We planned to calculate NNTs as the reciprocal of the absolute risk reduction (ARR; McQuay 1998). For unwanted effects, the NNT becomes the number needed to treat for an additional harmful outcome (NNH) and is calculated in the same manner. We planned to use dichotomous data to calculate risk ratio (RR) with 95% confidence intervals (CI) using a fixed-effect model unless we found significant statistical heterogeneity (see Assessment of heterogeneity). We planned not to use continuous data in analyses, and intended to extract and use continuous data, which probably reflects efficacy and utility poorly, only if useful for illustrative purposes only.

**Unit of analysis issues**

We accepted randomisation to individual participant only. We planned to split the control treatment arm between active treatment arms in a single study if the active treatment arms were not combined for analysis.

**Dealing with missing data**

We planned to use intention-to-treat (ITT) analysis where the ITT population consisted of participants who were randomised, took at least one dose of the assigned study medication, and provided at least one post-baseline assessment. We planned to assign zero improvement to missing participants wherever possible.

**Assessment of heterogeneity**

We planned to deal with clinical heterogeneity by combining studies that examined similar conditions. We planned to assess statistical heterogeneity visually (L’Abbé 1987), and using the $I^2$ statistic. When the $I^2$ value was greater than 50%, we intended to consider possible reasons for this.

**Assessment of reporting biases**

The aim of this review was to use dichotomous outcomes of known utility and of value to people with pain (Hoffman 2010; Moore 2010c; Moore 2010d; Moore 2010e; Moore 2013b). The review would not depend on what the authors of the original studies chose to report or not, though clearly difficulties might arise in studies that did not report any dichotomous results. We planned to assess publication bias using a method designed to detect the amount of unpublished data with a null effect required to make any result clinically irrelevant (usually taken to mean an NNT of 10 or higher; Moore 2008).

**Data synthesis**

We planned to use a fixed-effect model for meta-analysis. We would have used a random-effects model for meta-analysis if there was significant clinical heterogeneity and it was considered appropriate to combine studies. We planned to analyse data for each neuropathic pain condition in three tiers, according to outcome and freedom from known sources of bias.
1. The first tier would use data meeting current best standards, where studies report the outcome of at least 50% pain intensity reduction over baseline (or its equivalent), without the use of LOCF or other imputation method for drop-outs, report an ITT analysis, last eight or more weeks, have a parallel-group design, and have at least 200 participants (preferably at least 400) in the comparison (Moore 1998; Moore 2010a; Moore 2012a; Moore 2012b). We would report these first-tier results first.

2. The second tier would use data from at least 200 participants but where one or more of the first-tier conditions above was not met (reporting at least 30% pain intensity reduction, using LOCF or a completer analysis, or lasting four to eight weeks).

3. The third tier of evidence would relate to data from fewer than 200 participants, or where there were expected to be significant problems because, for example, of very short duration studies of less than four weeks; where there was major heterogeneity between studies; or where there were shortcomings in allocation concealment, attrition, or incomplete outcome data. For this third tier of evidence, no data synthesis is reasonable and may be misleading, but an indication of beneficial effects might be possible.

Subgroup analysis and investigation of heterogeneity
We planned to carry out analyses according to individual neuropathic pain conditions because placebo response rates for the same outcome can vary between conditions, as can the drug-specific effects (Moore 2009). We did not plan subgroup analyses since experience of previous reviews indicated that there would be too few data for any meaningful subgroup analysis (Gaskell 2014; McNicol 2013).

Sensitivity analysis
We planned no sensitivity analysis because the evidence base was known to be too small to allow reliable analysis; we would not pool results from neuropathic pain of different origins in the primary analyses. We planned to examine details of dose-escalation schedules in the unlikely situation that this could provide some basis for a sensitivity analysis.

RESULTS
Description of studies
Results of the search
Electronic searches identified 10 possible studies for inclusion, and searches of ClinicalTrials.gov identified one study. Figure 1 shows the flow diagram of study selection. No study matched the inclusion criteria. We did not identify any studies testing the effects of buprenorphine in neuropathic pain that satisfied our inclusion criteria.

Included studies
There were no included studies.

Excluded studies
We excluded 11 studies. Two were reviews with no primary clinical trial data (Kress 2009; Sirl 2005). Five were randomised trials, but included a mix of pain conditions, including musculoskeletal pain and cancer pain, and did not report results for the (often few) participants with neuropathic pain (Böhme 2003; Landau 2007; NCT00312195; Sirl 2003; Sorge 2004). Two were not double-blind (Canneti 2013; Penza 2008), one was not randomised (Rodriguez-Lopez 2004), and one was a short duration study examining opioid conversion ratios in a small number of participants after surgery (Benedetti 1998).

Risk of bias in included studies
There were no studies to evaluate.

Effects of interventions
There were no studies to evaluate.

DISCUSSION
Summary of main results
We found no studies assessing the efficacy of buprenorphine in neuropathic pain to include in this review. Several studies, some randomised, had assessed buprenorphine, usually as a transdermal patch, in chronic pain. This was usually a mix of various types of pain, typically but not always with musculoskeletal pain predominating. None reported results by type of pain condition, and none of the studies provided a thorough assessment that any of the participants had pain with a neuropathic component. Using data from those studies would be little more than a guess. As best we know, there is no evidence to support or refute the use of buprenorphine for treating neuropathic pain. This is despite the fact that one UK survey found that weak and strong opioids were used frequently for treating neuropathic pain, either alone or in combination with other drugs (Hall 2013). The lack of evidence for long-term benefit with buprenorphine reflects a similar
result with oxycodone and other opioids (Gaskell 2014; McNicol 2013). The lack of evidence of efficacy combined with substantial evidence of harm has led to calls for referral to a pain management specialist (ideally with expertise in opioid use) if daily dosing exceeds 8 to 100 mg morphine equivalents a day, particularly if pain and function are not substantially improved (Franklin 2014).

**Overall completeness and applicability of evidence**

There was no evidence for inclusion.

**Quality of the evidence**

There was no evidence for inclusion.

**Potential biases in the review process**

We know of no potential biases in the review process. It is unlikely that there is a large body of unpublished evidence showing a large effect from buprenorphine in neuropathic pain.

**Agreements and disagreements with other studies or reviews**

This review agrees with previous reviews and Cochrane reviews that there appear to be no clinical studies specifically assessing the efficacy of buprenorphine, at any dose or formulation, in neuropathic pain (Kress 2009; McNicol 2013).

**AUTHORS’ CONCLUSIONS**

**Implications for practice**

**For clinicians**

There is insufficient evidence to support or refute the suggestion that buprenorphine has any efficacy in any neuropathic pain condition.

**For policy makers**

There is insufficient evidence to support or refute the suggestion that buprenorphine has any efficacy in any neuropathic pain condition. In the absence of any supporting evidence, it should probably not be recommended, except at the discretion of a pain specialist with particular expertise in opioid use.

**For funders**

There is insufficient evidence to support or refute the suggestion that buprenorphine has any efficacy in any neuropathic pain condition. In the absence of any supporting evidence, it should probably not be recommended, except at the discretion of a pain specialist with particular expertise in opioid use.

**Implications for research**

Large, robust randomised trials with patient-centred outcomes would be required to produce evidence to support or refute efficacy of buprenorphine in neuropathic pain. The necessary design of such trials is well established, but for opioids in neuropathic pain, the outcomes should be those of at least 30% and at least 50% pain intensity reduction over baseline at the end of a trial of 12 weeks’ duration in participants continuing on treatment. Withdrawal for any reason should be regarded as treatment failure, and LOCF analysis should not be used. The reason for this is that, in chronic pain, opioids frequently produce withdrawal rates of 50% or more, meaning that LOCF analysis can overstate treatment efficacy.

**ACKNOWLEDGEMENTS**

Institutional support is provided by the Oxford Pain Relief Trust. The National Institute for Health Research (NIHR) is the largest single funder of the Cochrane Pain, Palliative and Supportive Care Review Group.

Disclaimer: the views and opinions expressed herein are those of the review authors and do not necessarily reflect those of the NIHR, National Health Service (NHS), or the Department of Health.
Benedetti 1998 [published data only]

Böhme 2003 [published data only]

Canneti 2013 [published data only]

Kress 2009 [published data only]

Landau 2007 [published data only]

NCT00312195 [published data only]

Penza 2008 [published data only]

Rodriguez-Lopez 2004 [published data only]

Sittl 2003 [published data only]

Sittl 2005 [published data only]

Sorge 2004 [published data only]

Additional references

Bach 1991

Baron 2012

Bouhassira 2008

Budd 2004

Bullingham 1981

Bullingham 1983
Elkader 2005

Dahan 2006

Demant 2014

Derry 2012

Derry 2013

Derry 2014

Dworkin 2008

Elkader 2005

Filiz 2006

Finnerup 2013

Finnerup 2015

Foster 2013

Franklin 2014

Gal 1989

Gaskell 2014

Gustorff 2008

Hakl 2012

Hall 2008

Hall 2013

Hand 1990
Buprenorphine for neuropathic pain in adults (Review)

Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Helfert 2015

Higgins 2011

Hoffman 2010

Jadad 1996

Jensen 2011

Kalso 2013
Kalso E, Aldington DJ, Moore RA. Drugs for neuropathic pain. BMJ 2013;347:f7339. [DOI: 10.1136/bmj.f7339]

Katusic 1991

Koopman 2009

Kusnik 2008

L’Abbé 1987

Lange 2010

Liberati 2009

Licina 2013

Lunn 2014

McNicol 2013

McQuay 1998

McQuay 2007

Moore 2008

Moore 2009

Moore 2009

Moore 2010a
Moore 2010b

Moore 2010c

Moore 2010d

Moore 2010e

Moore 2011a

Moore 2011b

Moore 2012a

Moore 2012b

Moore 2013a

Moore 2013b

Moore 2014a

Moore 2014b

Moore 2014c

NICE 2012

NICE 2013

O’Brien 2010

Pace 2007

PaPaS 2012
Cochrane Pain, Palliative and Supportive Care Group (PaPaS) author and referee guidance. papas.cochrane.org/papas-documents (accessed 11 June 2015).

Pergolizzi 2010

Rappaport 1994
Sacerdote 2000

Sacerdote 2008

Staritz 1986

Straube 2008

Straube 2010

Sultan 2008

Torrance 2008

Treede 2008

van Hecke 2014

von Hehn 2012

Vos 2012

Walsh 2003

Weiner 2012

WHO 1996

Wiffen 2013

* Indicates the major publication for the study
### Characteristics of studies

**Characteristics of excluded studies**  *ordered by study ID*

<table>
<thead>
<tr>
<th>Study</th>
<th>Reason for exclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Benedetti 1998</td>
<td>Not randomised comparison of buprenorphine versus placebo; intravenous buprenorphine; short term</td>
</tr>
<tr>
<td>Böhme 2003</td>
<td>Various chronic pain diagnoses, plus cancer</td>
</tr>
<tr>
<td>Canneti 2013</td>
<td>Not double-blind</td>
</tr>
<tr>
<td>Kress 2009</td>
<td>Review</td>
</tr>
<tr>
<td>Landau 2007</td>
<td>75% of participants had pain of back, knee, or hip. Not neuropathic pain</td>
</tr>
<tr>
<td>NCT00312195</td>
<td>Non-cancer pain, without separate description of neuropathic pain</td>
</tr>
<tr>
<td>Penza 2008</td>
<td>Not double-blind</td>
</tr>
<tr>
<td>Rodriguez-Lopez 2004</td>
<td>Not a randomised controlled trial</td>
</tr>
<tr>
<td>Sittl 2003</td>
<td>Fewer than 20% participants had neuropathic pain, not separately described</td>
</tr>
<tr>
<td>Sittl 2005</td>
<td>Review</td>
</tr>
<tr>
<td>Sorge 2004</td>
<td>Various chronic pain diagnoses, plus cancer</td>
</tr>
</tbody>
</table>
DATA AND ANALYSES

This review has no analyses.

WHAT’S NEW

<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>11 October 2017</td>
<td>Review declared as stable</td>
<td>No new studies likely to change the conclusions are expected</td>
</tr>
</tbody>
</table>

HISTORY

<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>7 June 2017</td>
<td>Review declared as stable</td>
<td>See Published notes.</td>
</tr>
</tbody>
</table>

CONTRIBUTIONS OF AUTHORS

SD and RAM wrote the protocol.
SD, PW, and RAM searched for and selected studies for inclusion, and carried out data extraction.
All review authors were involved in writing the full review.
RAM will be responsible for any updates required.

DECLARATIONS OF INTEREST

PW has no conflicts relating to this review or any similar product.
SD has no conflicts relating to this review or any similar product.
RAM has no conflicts relating to this review or any similar product.
CS has no conflicts relating to this review or any similar product.
DA has no conflicts relating to this review or any similar product.
PC has no conflicts relating to this review or any similar product.
RK has no conflicts relating to this review or any similar product.

We are funded by the NIHR for work on a series of reviews informing the unmet need of chronic pain and providing the evidence for treatments of pain.
SOURCES OF SUPPORT

Internal sources

• Oxford Pain Relief Trust, UK.
General institutional support

External sources

• The National Institute for Health Research (NIHR), UK.
NIHR Cochrane Programme Grant: 13/89/29 - Addressing the unmet need of chronic pain: providing the evidence for treatments of pain

DIFFERENCES BETWEEN PROTOCOL AND REVIEW

The protocol included both CRPS I and CRPS II as a diagnosis of neuropathic pain. We have now removed CRPS I because it is no longer considered to be neuropathic pain. There were no studies in CRPS I.

NOTES

A restricted search in June 2017 did not identify any potentially relevant studies likely to change the conclusions. We are not aware of any ongoing studies in this area. Therefore, this review has now been stabilised following discussion with the authors and editors. If appropriate, we will update the review if new evidence likely to change the conclusions is published, or if standards change substantially which necessitate major revisions.

INDEX TERMS

Medical Subject Headings (MeSH)

Analgesics, Opioid [*therapeutic use]; Buprenorphine [*therapeutic use]; Neuralgia [*drug therapy]

MeSH check words

Adult; Humans